Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Casesendocrinology-diabetes-and-growth

Paeds Cases · endocrinology-diabetes-and-growth

Counselling the family of a survivor starting hormone replacement — OSCE

OSCE communication and shared decision-making station: explaining to the parents of a 9-year-old medulloblastoma survivor what the new endocrine late effects mean — why the slowing growth velocity and delayed bone age are growth hormone deficiency from the cranial radiation, what the recombinant growth hormone therapy involves including the prerequisite magnetic resonance imaging, the dose, the route and the monitoring, what the sick-day hydrocortisone education means for the concurrent ACTH deficiency, and what the lifelong surveillance and the transition to adult care will involve — while addressing parental anxiety about recurrence, injection burden, and the long-term outlook.

osce communication and shared decision-making2 min readVerification in progress

Target exams

MRCPCH ClinicalRACP DCERCPSC Pediatrics
On this page
Study tools

Target exams

MRCPCH ClinicalRACP DCERCPSC Pediatrics
Prompt
The parents of a 9-year-old boy sit with you in the long-term follow-up clinic. He was treated for a medulloblastoma at age 5 with surgery, craniospinal radiation (36 Gy with a posterior fossa boost) and chemotherapy, and he is now three years off therapy with no evidence of recurrence. His growth has slowed over the past year, his bone age is delayed, and the work-up has confirmed growth hormone deficiency with a low IGF-1 and a peak growth hormone of 4 ng/mL on two stimulation tests. A morning cortisol has also returned low, suggesting ACTH deficiency. You are about to start hydrocortisone and, once the scheduled magnetic resonance imaging scan confirms stable disease, recombinant growth hormone. The parents are frightened that the growth failure means the tumour is back, worried about what daily treatment will involve, and unsure what the future holds. Counsel them.

A strong candidate frames the conversation around the three questions the parents are really asking — is the cancer back, what will we do, and what will happen — and addresses the fear of recurrence directly before anything else. The slowing growth is explained in plain language as a recognised and treatable consequence of the cranial radiation that cured the tumour, not a sign that the tumour has returned: the radiation that saved his life has slowed the gland that produces the growth signal, so the bones are not growing at the normal rate, and this was an expected and anticipated possibility at the three-year mark. The scheduled magnetic resonance imaging scan is framed as the routine confirmation of stable disease that must precede the growth hormone therapy, not as an investigation driven by a new suspicion of recurrence. [1] [3]

The therapy discussion covers the two hormone problems honestly and in sequence. The low cortisol is addressed first and framed as the more urgent of the two, because cortisol is what the body uses to cope with stress and infection: the boy will take a small daily dose of hydrocortisone to replace what his gland cannot make, and the parents are taught the sick-day rules — doubling or tripling the dose during a fever, and giving the emergency injection if he vomits or becomes unwell — because missing this is the one preventable emergency in his future. The growth hormone therapy is explained as a daily subcutaneous injection at bedtime to mimic the body's natural overnight signal, with the dose adjusted to a blood test (the IGF-1), and the family is reassured that the response is best when treatment is started early and taken consistently. [2]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this case. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References3ShowHide
  1. [1]Chemaitilly W, Sklar CA. Childhood Cancer Treatments and Associated Endocrine Late Effects: A Concise Guide for the Pediatric Endocrinologist. Horm Res Paediatr, 2019.PMID 30404091
  2. [2]Sklar CA, et al. Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2018.PMID 29982476
  3. [3]Chemaitilly W, et al. Endocrine Late Effects in Childhood Cancer Survivors. J Clin Oncol, 2018.PMID 29874130
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousCounselling a family starting recombinant growth hormone therapy — OSCEendocrinology-diabetes-and-growthNextCushing syndrome in children — structured clinical encounterendocrinology-diabetes-and-growth